InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$94.75

2026-10-16

Market Cap

$121.2B

Volume

29.7M

52-Wk High

$106.33

52-Wk Low

$73.31

Trailing PE

23.2

P/S

3.23

Gross Margin

66.7%

Net Margin

13.9%

ROE

11%

ROIC

6%

Piotroski

9/9

Altman Z

3.0

1-Yr Return

+3.0%

5-Yr Return

+9.1%

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

SectorHealthcareIndustryMedical - DevicesExchangeNYSEMarket Cap$121.2BEmployees95,000 (SEC-filed)CEOGeoffrey Straub MarthaIPO1973-05-02CountryIE

Building Two, Parkmore Business Park West, Galway, GA H91 4K49 · Tel 353 1 438 1700 · medtronic.com

INSIDERSTREET SCORE64 / 100Street mean $102.09 (11 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$6M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · MDT +3.0% · S&P 500 +15.9% · spread -12.9pp

7 Years vs S&P 500 · MDT +9.1% · S&P 500 +189.9% · spread -180.7pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE64of 100

Score Breakdown

Profitability	57/100
Growth	55/100
Momentum	83/100
Quality	83/100
Earnings Quality	93/100
Balance Sheet	70/100
Value	64/100
Risk (safety)	65/100
Overall	63.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
SYK	74
ABT	57
BSX	67
EW	65
DXCM	81
ZBH	60
MDT	64

IS Score Trend — quarterly

17 quarters, 23 Q1 to 27 Q1. Peak 64 in 27 Q1, latest 64 — +0 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY64 / 100IS Score 63.6 / 100 · +0.0 from peak of 64

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 85 / 100 · Power +70 · 20 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 64 and price structure at 85 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 63.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 63 → 63 → 59 → 64	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 2,293 → now 2,130	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)2 buys2026-09-11

Insider Buys (180d)0none disclosed

ETF Funds (30d)579 up / 487 downnet +92 funds

Institutions Added (13F)-94managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 2,293 · latest 2,130 (-163 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	2,130	1100.4M	$85.3B	86.0%
2026 Q1	2,224	1093.3M	$93.6B	85.4%
2025 Q4	2,293	1094.0M	$102.6B	85.5%
2025 Q3	2,148	1075.1M	$100.2B	84.0%
2025 Q2	2,119	1082.5M	$92.3B	84.6%
2025 Q1	2,152	1078.3M	$96.0B	84.2%
2024 Q4	2,099	1065.2M	$83.1B	83.2%
2024 Q3	2,034	1049.9M	$92.3B	82.0%
2024 Q2	1,997	1060.7M	$81.5B	82.9%
2024 Q1	2,041	1093.6M	$92.3B	85.5%
2023 Q4	2,040	1087.3M	$87.0B	85.0%
2023 Q3	1,929	1087.8M	$83.1B	85.0%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Marinaro Michael	EVP, Pres MedSurg and Americas	2026-10-15	SELL	10,420	$1.00M	105,916
Martha Geoffrey	director, Chairman and CEO	2026-10-15	SELL	50,000	$4.75M	277,866
Kiil Harry Skip	EVP & President Cardiovascular	2026-09-16	SELL	1,483	$0.14M	42,186
Blomquist Denise L.	Chief Accounting Officer	2026-09-15	GIFT	600	—	16,398
Marinaro Michael	EVP, Pres MedSurg and Americas	2026-08-20	TAX W/H	1,084	$0.10M	116,336
Thompson Kweli	EVP & President, Neuroscience	2026-08-03	A-Award	6,923	—	35,390
Thompson Kweli	EVP & President, Neuroscience	2026-08-03	A-Award	17,306	—	17,306
Thompson Kweli	EVP & President, Neuroscience	2026-08-03	A-Award	49,167	$4.26M	49,167

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	6	69,194	$6.5M	Counted
M — Exercises (paired A/D)	6	151,355	—	None — mechanics
F — Tax withholding	24	93,305	$7.9M	None — compensation
G — Gifts	1	600	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$6.5M6 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-10-15	Martha Geoffrey	50,000	$4.8M
2026-10-15	Marinaro Michael	10,420	$1.0M
2026-09-16	Kiil Harry Skip	1,483	$0.1M
2026-07-08	Walter Matthew R.	3,102	$0.3M
Trailing 12 mo	8 filings	160,323	$15M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Form	Reporting person	% of class	Shares
2026-04-28	SCHEDULE 13G	Vanguard Capital Management	7.51%	96.4M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-12-03	SCHEDULE 13G/A	The Vanguard Group	10.21%	130.9M sh
2025-04-23	SCHEDULE 13G/A	BlackRock, Inc.	6.90%	88.7M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-11	2026-10-09
Kevin Hern	House	SELL	$15,001 - $50,000	2026-08-24	2026-09-02
Kevin Hern	House	SELL	$15,001 - $50,000	2026-08-24	2026-09-02
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-20
Tommy Tuberville	Senate	SELL	$15,001 - $50,000	2024-08-26	2026-08-05
Thomas Hawley Tuberville	Senate	SELL	$15,001 - $50,000	2024-08-26	2026-08-05

House 12-Mo20 trades3 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)2,224

13F Shares1.09B85.4% of shares out

New / Closed184 / 209positions, QoQ

Increased / Reduced901 / 884positions, QoQ

Put/Call (13F)0.89option positions

Free Float99.9%1.28B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Fort Washington Investment Advisor	2.5M	$218M
Saratoga Research & Investment Man	1.2M	$105M
Davenport & Co Llc	1.1M	$95M
Wealth Enhancement Advisory Servic	1.1M	$84M
Congress Asset Management Co	883,081	$76M
Vontobel Holding Ltd.	711,019	$61M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.2%	$3.5B
VTSAX	0.2%	$3.5B
VSMPX	0.2%	$3.5B
VTI	0.2%	$3.5B
VFIAX	0.2%	$2.9B
VOO	0.2%	$2.9B

13F Filers Holding MDT — quarterly

Institutional Put/Call — quarterly

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session41.7%2026-10-15

20-Day Avg54.1%50-day 44.1%

TrendRising20d vs 50d

By Market CenterQ: 42% · N: 42% · B: 82%latest session

Weekly Notional ($B)

Where MDT Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Ubsa Ubs Ats	8.9M	76 sh
Incr Intelligent Cross Llc	7.6M	64 sh
Ebxl Level Ats	5.1M	50 sh
Sgmt Sigma X2	4.3M	69 sh
Bids Bids Ats	4.2M	465 sh
Pure Purestream	3.5M	48 sh

Where a dollar of Medtronic plc revenue goes. All values FY2026 filings, live.

Region	Revenue	Share
UNITED STATES	$71.4B	80%
Total Other Countries, Excluding United States and Ireland	$18.1B	20%
IRELAND	$143M	0%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

MDT (live moat model)Peer median: SYK · ABT · BSX · EW · DXCM

Component scores from the live moat model. Peer median illustrative.

Moat score 84/100 — Wide; primary source Cost Advantage.

3.8 · Employees (SEC filings)

Officer	Title
Thierry Pieton	Executive Vice President & Chief Financial Officer
Geoffrey Straub Martha	Chairman of the Board & Chief Executive Officer
Michelle Quinn	Executive Vice President, General Counsel & Secretary
Brett A. Wall	Executive Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)4 of 6recent quarters

Avg Surprise+2.5%

Next Report2026-11-17

Income Quality1.52OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY22	FY23	FY24	FY25	FY26
Revenue	+5.2%	-1.4%	+3.6%	+3.6%	+8.4%
Gross profit	+9.7%	-4.8%	+3.1%	+3.6%	+7.9%
Operating income	+28.3%	-4.6%	-6.2%	+15.8%	+8.6%
Net income	+39.7%	-25.4%	-2.2%	+26.8%	+3.0%

$B · FY ends	FY22	FY23	FY24	FY25	FY26
Revenue	31.7	31.2	32.4	33.5	36.4
Cost of revenue	10.1	10.7	11.2	11.6	12.7
Gross profit	21.5	20.5	21.1	21.9	23.6
R&D expense	2.7	2.7	2.7	2.7	2.9
SG&A expense	10.3	10.4	10.7	10.8	11.8
Operating income	5.8	5.5	5.1	6.0	6.5
EBITDA	8.8	8.7	8.2	9.2	9.8
D&A	2.7	2.7	2.6	2.9	3.0
Pretax income	5.5	5.4	4.8	5.6	6.1
Income tax	0.5	1.6	1.1	0.9	1.3
Net income	5.0	3.8	3.7	4.7	4.8
Diluted EPS ($)	3.73	2.82	2.76	3.61	3.73
Diluted shares (M)	1,351	1,333	1,330	1,290	1,288

Operating CF$7B

CapEx$2B

Free cash flow$5B

SBC$0B

Buybacks$1B

Net cash change$-0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY23	FY24	FY25	FY26
Cash & equivalents	1.5	1.3	2.2	1.9
ST investments	6.4	6.7	6.7	7.3
Receivables (net)	6.0	6.1	6.5	6.6
Total current assets	21.7	21.9	23.8	24.8
PP&E (net)	5.6	6.1	6.8	7.4
Goodwill + intangibles	56.3	54.2	53.4	52.7
Total assets	90.9	90.0	91.7	93.0
Accounts payable	2.7	2.4	2.4	2.6
Short-term debt	0.0	1.1	2.9	1.8
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	9.1	10.8	12.9	11.7
Long-term debt	24.3	23.9	25.6	26.1
Total liabilities	39.3	39.6	43.4	43.0
Shareholders' equity	51.7	50.4	48.3	50.1

Cash Flow Statement — Full

$B	FY23	FY24	FY25	FY26
Net income	3.8	3.7	4.7	4.8
D&A	2.7	2.6	2.9	3.0
Stock-based compensation	0.4	0.4	0.4	0.5
Working capital change	(1.0)	(0.5)	(1.1)	(1.4)
Operating cash flow	6.0	6.8	7.0	7.3
Capital expenditures	(1.5)	(1.6)	(1.9)	(1.9)
Investing cash flow	(3.5)	(2.4)	(1.9)	(2.9)
Buybacks	(0.6)	(2.1)	(3.2)	(1.0)
Dividends paid	(3.6)	(3.7)	(3.6)	(3.6)
Debt issuance / (repay)	(0.6)	1.1	2.1	(1.2)
Financing cash flow	(5.0)	(4.5)	(4.4)	(4.8)
Free cash flow	4.6	5.2	5.2	5.4

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
PROFITABILITY
ROE	9.7%	7.2%	7.2%	9.5%	9.8%	11%
ROA	5.5%	4.1%	4.1%	5.1%	5.2%	5.6%
ROIC	8.0%	5.7%	5.9%	7.3%	7.5%	6.4%
Gross margin	68.0%	65.7%	65.3%	65.3%	65.0%	66.7%
Operating margin	18.2%	17.6%	15.9%	17.8%	17.8%	18.1%
Net margin	15.9%	12.0%	11.4%	13.9%	13.2%	13.9%
EBITDA margin	27.7%	27.9%	25.3%	27.5%	27.0%	27.1%
FCF margin	18.9%	14.7%	16.1%	15.5%	14.9%	—
VALUATION
P/E	24.83	29.72	27.55	23.04	22.36	23.2
P/B	2.38	2.17	2.02	2.24	2.17	2.4
P/S	3.95	3.58	3.13	3.20	2.95	3.23
P/FCF	20.93	24.38	19.47	20.72	19.78	19.8
EV/EBITDA	15.80	14.73	14.42	13.78	12.97	14.5
EV/Revenue	4.38	4.10	3.65	3.79	3.47	3.9
Earnings yield	4.0%	3.4%	3.6%	4.3%	4.5%	4.31%
FCF yield	4.8%	4.1%	5.1%	4.8%	5.1%	5.06%

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
LEVERAGE & SOLVENCY
Current ratio	1.86	2.39	2.03	1.85	2.13	2.07
Quick ratio	1.49	1.81	1.55	1.42	1.62	2.09
Debt / equity	0.46	0.47	0.50	0.59	0.57	0.56
Debt / assets	26.5%	26.8%	27.8%	31.1%	30.1%	30.2%
Net debt / EBITDA	1.54	1.89	2.08	2.12	1.93	2.60
Interest coverage	10.98	9.44	7.74	8.72	9.58	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
EFFICIENCY
Asset turnover	0.34	0.34	0.36	0.37	0.39	0.40
Receivables turnover	5.75	5.41	5.34	5.31	5.53	167.6
DSO (days)	63	67	68	69	66	2
DPO (days)	79	84	83	76	73	79
Cash conversion cycle	145	152	157	160	157	-83
GROWTH (YoY)
Revenue growth	5.2%	-1.4%	3.6%	3.6%	8.4%	—
Net income growth	39.7%	-25.4%	-2.2%	26.8%	2.9%	—
EPS growth	41.1%	-24.8%	-1.6%	30.6%	2.9%	—
FCF growth	22.4%	-23.4%	13.5%	-0.3%	4.6%	—
PER SHARE ($)
EPS (diluted, TTM)	3.75	2.82	2.77	3.62	3.73	4.09
Book value / share	39.07	38.63	37.89	37.29	38.40	39.73
Revenue / share	23.56	23.43	24.42	26.04	28.23	29.33
FCF / share	4.44	3.44	3.92	4.03	4.21	4.79
Cash / share	7.86	5.97	6.04	6.96	7.16	6.89
SHAREHOLDER RETURN & SCORES
Buyback yield	2.0%	0.6%	2.1%	3.0%	1.0%	1.07%
Altman Z-Score	3.14	2.90	2.72	2.70	2.79	3.0
Piotroski F-Score	8	5	5	7	8	9/9
Beneish M-Score	-2.60	-2.49	-2.64	-2.54	-2.67	-3.44

Model	Score	Zone	Note
Piotroski F-Score	9 / 9	Strong
Altman Z-Score	3.0	Safe (>2.99)	Grey
Income quality	1.52	Cash-backed	OCF ÷ net income
Beneish M-Score	-3.44	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.79
Interest burden	0.90
Operating margin	19.5%
Asset turnover	0.41×
Financial leverage	1.88×
= ROE	11%

Growth Quality (live)	Value
Revenue stability	0.73
Earnings stability	0.17
Earnings persistence	0.95
Revenue CAGR 3y	6.0%
EPS CAGR 3y	14.5%
FCF CAGR 3y	11.3%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield1.07%

Dividend Yield3.02%

Total Shareholder Return4.00%cash yield

SBC / Revenue1.3%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
SYK	$113.0B	30.3	17%	19.4%	+8.5%	9/9	-20.2%
ABT	$181.5B	33.7	11%	7.4%	+8.1%	5/9	-17.8%
BSX	$64.3B	17.9	15%	16.7%	+13.5%	8/9	-54.6%
EW	$49.9B	49.8	9%	13.9%	+14.6%	6/9	+19.2%
DXCM	$32.5B	33.2	38%	19.0%	+15.5%	9/9	—
ZBH	$18.1B	23.0	6%	9.1%	+8.6%	6/9	—
PEN	$12.6B	78.4	11%	8.9%	+17.6%	6/9	—
SNN	$12.2B	19.0	22%	9.8%	+11.5%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

51 Analysts

Str Sell (0)Sell (0)Hold (20)Buy (30)Str Buy (1)

Mean Target (qtr)$102.0911 targets

Target vs. Price+7.7%last-quarter mean

Next Report2026-11-17street $1.34

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$36.15B	$36.18B / $36.13B	$5.52	$5.62 / $5.49	18
FY2026	$36.15B	$36.18B / $36.13B	$5.52	$5.62 / $5.49	14
FY2027	$39.05B	$39.21B / $38.52B	$5.98	$6.00 / $5.97	16

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$97.00	+2.4%	2
Last Quarter	$102.09	+7.7%	11
Last Year	$102.04	+7.7%	46
All Time	$104.84	+10.6%	109

Rolling mean of published targets vs. last close $94.75. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

5/5

ROE

3/5

ROA

4/5

Debt/Eq

1/5

P/E

2/5

P/B

3/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

MDT +3.0% vs S&P 500 +15.9% — spread -12.9pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$89.39	+5.36	+6.00%	Above
SMA 50	$90.38	+4.37	+4.84%	Above
SMA 200	$86.94	+7.81	+8.98%	Above
EMA 9	$92.04	+2.71	+2.94%	Above
EMA 21	$90.55	+4.20	+4.64%	Above
EMA 50	$89.21	+5.54	+6.21%	Above
EMA 200	$87.01	+7.74	+8.90%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +7020 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%82

Volume 20%94

Volatility 10%100

Patterns 15%38

This Week100% bullishof 11 price-based votes

4 Weeks Ago73%+27 pts since

12 Weeks Ago45%+55 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$89.39

Price vs SMA 50$90.38

Price vs SMA 200$86.94

EMA 9/21 Cross92.0/90.5

SMA 50/200Golden

ADX DirectionADX 23

Supertrend$88

Parabolic SAR$88

SMA Slope0.170

RSI64.6

Stochastic K/D91/94

StochRSI K/D97/99

Williams %R-16

CCI160

TSI vs Signal13.2

CMO29.3

ROC9.69%

OBV SignalAccum

Chaikin MF0.070

MFI73

Force Index33M

Elder Ray Bull5.95

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 94

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$95.22 / $96.47 / $97.50	S1 / S2	$94.19 / $92.94
Bollinger (20,2)	$83.50 – $95.29	Squeeze	Off
52-wk range	$72.07 – $102.92	Off 52-wk high	-7.9%
ATR (14)	$2.39 (2.5%)	Historical vol	25.7%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+2.5%Jan70%

-1.0%Feb55%

+0.1%Mar48%

+2.0%Apr55%

+0.2%May60%

-0.0%Jun40%

+1.9%Jul80%

+0.2%Aug60%

-1.0%Sep40%

-1.2%Oct45%

+1.9%Nov60%

+0.7%Dec50%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	MDT	S&P 500
Weekly volatility (σ, 1y)	3.65%	1.83%
Best / worst week (1y)	+9.1% / -6.1%	—
Max drawdown (5y, monthly)	-40.1%	—
1-week VaR (95%)	-5.2%	—
Beta (5y)	0.57	1.00

MDT EQUITY WEATHER (LIVE)PARTLY CLOUDY · +23

Trend+41

Momentum+65

Volume+30

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 437 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+22.6+42.8 vs industry

Trend+41.0+63.1 vs industry

Momentum+65.0+87.0 vs industry

Volume+30.4+35.4 vs industry

Reading	MDT	Medical - Devices n=524	Healthcare n=5,272	All US symbols n=70,435
Overall	+22.6	-20.2	-24.0	-20.5
Trend	+41.0	-22.1	-25.6	-21.3
Momentum	+65.0	-22.0	-28.5	-15.8
Volume	+30.4	-5.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Geoff Martha Chairman and Chief Executive Of	$22.9M	70% equity+incentive
Thierry Piéton EVP, Chief Financial Officer	$8.6M	48% equity+incentive
Brett Wall Former EVP & President, Neuroscie	$6.9M	63% equity+incentive
Mike Marinaro EVP & President Medical Surgic	$6.8M	66% equity+incentive
Michelle Quinn EVP, General Counsel and Secr	$6.7M	61% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	77
Social	66
Governance	64
Composite ESG	69

Composite ESG Trend

Filed	8-K contents	Items
2026-09-17	Other Events; Exhibits	8.01,9.01
2026-09-01	Earnings Release; Exhibits	2.02,9.01
2026-06-03	Earnings Release; Exhibits	2.02,9.01
2026-05-18	Officer/Director Change; Exhibits	5.02,9.01
2026-04-27	Regulation FD; Exhibits	7.01,9.01
2026-03-24	Regulation FD	7.01
2026-02-17	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-11-18	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2021 to 2026
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-24 to 2026-09-01
Analyst estimates	dim/forward_estimates	3 rows · 2026-04-24 to 2027-04-24
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	62 rows · 2010 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-03 to 2026-10-15
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-04-23 to 2026-04-28
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Medtronic plc (MDT)

Medtronic plc (MDT)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Medtronic plc (MDT)

Institutions holding — 12 quarters

Medtronic plc (MDT)

Monthly Net Insider Flow (000 shares)

Signal Summary

Medtronic plc (MDT)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding MDT — quarterly

Institutional Put/Call — quarterly

Medtronic plc (MDT)

Where MDT Trades in the Dark

Medtronic plc (MDT)

3.8 · Employees (SEC filings)

Medtronic plc (MDT)

Medtronic plc (MDT)

Medtronic plc (MDT)

Balance Sheet — Full

Cash Flow Statement — Full

Medtronic plc (MDT)

Medtronic plc (MDT)

Medtronic plc (MDT)

Medtronic plc (MDT)

Street Price Target — Trajectory

Third-Party Composite Rating

Medtronic plc (MDT)

Medtronic plc (MDT)

Family Scores (site weights)

Medtronic plc (MDT)

Medtronic plc (MDT)

Medtronic plc (MDT)